TARGED TARGETED ENZYME DELIVERY
Live / Applied — Non-final action mailed (as of 11 Feb 2026)
What this means for you
Not registered yet, but its 22 Aug 2025 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 79437611
- Mark type
- Design + words
- Filed
- 22 Aug 2025
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations; medical preparations; dietary supplements for medical purposes; medicinal herbs and extracts; drugs for medical purposes, pharmaceutical preparations for the prevention and treatment of thrombosis; antithrombotic agents; thrombolytic drugs; coagulation inhibitors; anticoagulants; platelet aggregation inhibitors; hemostatic agents; blood thinners for medical use; therapeutic compounds for thrombosis; pharmaceutical preparations for cardiovascular diseases; pharmaceutical preparations for blood clotting disorders; injectable or intravenous solutions for thrombosis treatment; medicinal products for the treatment of deep vein thrombosis (DVT); medicinal products for pulmonary embolism (PE) management; preclinical or clinical trial medicines for thrombosis research; pharmaceuticals for vascular diseases.
- Class 042 — Scientific and technological services: Scientific and technological services; research and development services; laboratory and clinical testing; biotechnology research services; pharmaceutical research services; medical and scientific laboratory services; medical research and development services; research and development in the field of thrombosis treatment; pharmaceutical and biotechnology research for antithrombotic drugs; preclinical and clinical testing of drugs for thrombosis; drug discovery services related to thrombosis; development of biopharmaceuticals for cardiovascular diseases; research in the field of platelet aggregation inhibitors; consultancy services in pharmaceutical research and development; scientific studies related to thrombosis and blood clotting disorders; clinical trials for thrombosis drugs and therapies; design and implementation of drug efficacy studies for thrombosis treatment; genetic research and molecular biology services related to thrombosis; technical data analysis and providing non-downloadable computer software for use in modeling in the field of thrombosis treatment; laboratory services for thrombosis diagnosis and testing; research services related to anticoagulation therapy; research in personalized medicine for thrombosis patients; reference material certification services [quality assessment] in the field of thrombosis treatments; research and development services for biotechnological solutions for thrombosis; scientific advisory and consultation services in thrombosis research.
Owner
Prosecution history
- 26 Feb 2026 — REFUSAL PROCESSED BY IB
- 12 Feb 2026 — NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
- 11 Feb 2026 — REFUSAL PROCESSED BY MPU
- 15 Jan 2026 — NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
- 14 Jan 2026 — NON-FINAL ACTION WRITTEN
- 07 Jan 2026 — ASSIGNED TO EXAMINER
- 28 Nov 2025 — APPLICATION FILING RECEIPT MAILED
- 28 Nov 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 27 Nov 2025 — SN ASSIGNED FOR SECT 66A APPL FROM IB